Innovative Companies

Innovative Molecules is a clinical-stage biotechnology company based in Munich, Germany, dedicated to developing transformative therapies for herpes simplex virus (HSV) infections. The company's lead program is adibelivir (IM-250), a novel, orally available selective HSV-helicase primase inhibitor designed to block viral DNA replication directly. Unlike traditional nucleoside analogs, adibelivir targets the helicase-primase complex, offering potential for improved potency and the ability to address resistant strains. The company recently completed a Phase 1 clinical program and is advancing into Phase 2 trials for genital herpes and herpes encephalitis. Innovative Molecules aims to provide more effective and convenient treatment options for underserved patient populations suffering from severe or recurrent herpes-mediated diseases.